Xeris Biopharma (NASDAQ:XERS) Insider Sells 15,000 Shares

by · The Cerbat Gem

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) insider Kevin Mcculloch sold 15,000 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $8.02, for a total value of $120,300.00. Following the sale, the insider owned 1,676,126 shares of the company’s stock, valued at approximately $13,442,530.52. This represents a 0.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Mcculloch also recently made the following trade(s):

  • On Wednesday, July 1st, Kevin Mcculloch sold 90,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.03, for a total value of $722,700.00.

Xeris Biopharma Price Performance

NASDAQ XERS traded up $0.06 during trading on Tuesday, hitting $8.19. 1,838,477 shares of the company’s stock were exchanged, compared to its average volume of 1,872,077. The company has a market cap of $1.41 billion, a PE ratio of 136.50 and a beta of 0.66. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $5.25 and a fifty-two week high of $10.08. The stock’s 50 day moving average price is $7.55 and its two-hundred day moving average price is $6.78.

Xeris Biopharma (NASDAQ:XERS – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. Research analysts expect that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $10.80.

View Our Latest Stock Report on Xeris Biopharma

Hedge Funds Weigh In On Xeris Biopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Kestra Advisory Services LLC bought a new position in shares of Xeris Biopharma during the fourth quarter valued at $25,000. KBC Group NV bought a new stake in shares of Xeris Biopharma in the first quarter worth $27,000. Caitong International Asset Management Co. Ltd increased its holdings in Xeris Biopharma by 9,276.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock valued at $59,000 after purchasing an additional 7,421 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in Xeris Biopharma by 29.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after purchasing an additional 1,820 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its position in Xeris Biopharma by 179.3% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after purchasing an additional 5,000 shares during the last quarter. 42.75% of the stock is currently owned by institutional investors and hedge funds.

About Xeris Biopharma

(Get Free Report)

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.

Featured Stories